- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02261922
Ticagrelor and Endothelial Function
A Prospective Randomized Double Blind Study to Evaluate the Effect of Ticagrelor on Endothelial Function
Study Overview
Status
Intervention / Treatment
Detailed Description
Objective:
Demonstrate an improvement in endothelial function with ticagrelor
Introduction and hypothesis:
Ticagrelor and prasugrel are 2 new platelet antagonists. Both are superior to clopidogrel when used in acute coronary syndromes. However, only ticagrelor reduced cardiovascular mortality by almost 20%. Prasugrel reduced the composite clinical end point of cardiovascular mortality, myocardial infarction and stroke, but did not decrease mortality. The exact mechanism of mortality reduction with ticagrelor is unclear.
Some side effects of ticagrelor, such as brady-arrhythmias and dyspnea may be related to adenosine release. It is thus possible, that this drug may liberate significant amount of adenosine. Prior studies have demonstrated that adenosine has beneficial effects on the endothelial function and that it improves the outcome of patient with acute coronary syndromes.
It is thus possible that ticagrelor may improve endothelial function through an adenosine like effect. This effect is independent from platelet inhibition.
Prasugrel has the same platelet inhibition effect compared to ticagrelor, but our hypothesis is that it does not have an adenosine like effect and thus does not improve endothelial function.
Study design:
This is a prospective, randomized, double blind, cross-over study comparing 2 new platelet inhibitors that have the same potency: ticagrelor and prasugrel.
Patients with stable coronary artery disease will be randomized to one of these 2 drugs. Patients will receive one of the 2 drugs for a period of 8 +/- 2 days, they will then stop the drug for a period of 14 +/- 2 days, and they will then cross over and receive the other drug for a period of 8 +/- 2 days.
All patients will have the following measurements:
- Flow mediated Dilation (FMD) of the brachial artery
- Platelet aggregation in response to ADP
All measurements will be done at:
- Baseline 1 (prior to starting drug 1)
- At 8 +/- 2 days (peak effect of drug 1)
- Baseline 2 (at 14+/- 2 days; after washout and prior to starting drug 2)
- At 8 +/- 2 days after baseline 2 (peak effect of drug 2)
Measure of FMD of the brachial artery:
It will be performed according to the Academic Medical Center of Amsterdam pre-established protocol.
Measure of platelet aggregation:
It will be performed with the multiplate aggregometer
Study End-Points:
- Primary: change in FMD before and after each of the 2 drugs
- Secondary: Change in platelet aggregation before and after each of the 2 drugs
- Possible another secondary end-point: Change in NO activity in the blood before and after each of the 2 drugs
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Rabih Azar, MD, MPH
- Email: razar@usj.edu.lb
Study Locations
-
-
Beirut
-
Achrafieh, Beirut, Lebanon, Beirut
- Recruiting
- Hotel Dieu de France Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- - Prior MI > 1 year old
- Prior PCI > 1 year old
- Prior CABG > 3 months old
- Known lesion causing more than 50% stenosis on coronary angiography
Exclusion Criteria:
- Acute coronary syndrome within the last 6 months
- Any history of bleeding
- Age > 75 years
- Weight < 65 kg
- Prior stroke or TIA
- Platelet count < 100,000
- Hemoglobin < 11 mg/dL
- Patients who have received ticagrelor, prasugrel or clopidogrel in the 3 months that preceded randomization
- Patients who are taking anti-thrombotic therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ticagrelor
ticagrelor treatment
|
|
Active Comparator: prasugrel
prasugrel treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
flow mediated dilation of the brachial artery
Time Frame: 8 +/- 2 days
|
8 +/- 2 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FM240
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ticagrelor
-
Collegium Medicum w BydgoszczyCompleted
-
Federico II UniversityAdvicePharma GroupCompletedMyocardial Infarction | Coronary Artery Disease | Acute Coronary Syndrome | STEMI | NSTEMIItaly
-
University of FloridaCompleted
-
AstraZenecaParexelCompletedSickle Cell DiseaseGermany
-
University of FloridaAstraZenecaCompleted
-
University of FloridaThe Medicines CompanyCompletedCoronary Artery DiseaseUnited States
-
David AntoniucciAstraZeneca; A.R. CARD Onlus FoundationCompletedAcute Coronary Syndrome | Adverse Reaction to Antiplatelet AgentItaly, Greece
-
Centro Hospitalario La ConcepcionRecruiting
-
Sheba Medical CenterCompletedST Elevation Myocardial Infarction | Acute Coronary SyndromesIsrael
-
Cairo UniversityCompletedCardiovascular Diseases | Acute Coronary SyndromeEgypt